Since April 2017, the European Pharmacopeia allows to produce Water for Injection (WFI) using other methods than distillation. Meanwhile, the additional water quality "Highly Purified Water" (HPW) could be found in the Ph. Eur. but will be removed in April 2019. This means a huge change in the regulatory situation for the pharmaceutical companies. A new Q&A document had been launched by the EMA, but some topics remain unclear. Therefore, the ISPE D/A/CH CoP water and steam has discussed all questions extensively for 1.5 years and written down their position.
This webinar provided insight into the thoughts of the ISPE D/A/CH experts and additionally addresses the following questions:
Listen to Fritz Röder and a team of panelist as they discuss ten of the most asked or most interesting questions from the webinar in April 2019.
Fritz Roeder of Merck is based in Darmstadt, Germany and is an experienced project manager and engineer with broad knowledge in the pharmaceutical industry. He is an experienced speaker and author on a variety of pharmaceutical water topics.
Michael Clever of Roche is based in Penzberg, Germany and is an expert in the field of clean media operations with a strong engineering background in utility plants. He did a lot of research in the field of ultrafiltration and rouging.
Jochen Schmidt based in Basel, Switzerland, is the Process Utilities Lead at CRB. He has been working in the pharmaceutical water sector for more than 20 years with his main focus on the conception, process selection and dimensioning of complete water systems for the generation, storage and distribution of PW, WFI and pure steam.
Did you miss the webinar? Listen to the Water for Injection Using Non-Distillative Methods Webinar. Not a Member of ISPE? Join ISPE to gain access to all of our past webinars – and check out the webinar page to see all of the topics that have been discussed and what’s coming up.
Through the ISPE Foundation Professional Development Grant program, Silas Tamufor attended the 2023 ISPE Annual Meeting & Expo in October 2023. Tamufor is a PhD student and ISPE Boston Chapter member who began serving as the ISPE Boston Educational Programs Committee Chair in December 2023. He, along with 87 other students and recent graduates, attended the conference thanks to the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...